On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research entry: inclusion is for identification, not approval or a recommendation to use it. Verify the exact product and current US status with a pharmacist.
What the human evidence actually measures
The knee-pain report measured symptom reports after treatment; it did not test a molecular healing mechanism. Proposed repair mechanisms should be distinguished from demonstrated repair of a human tendon, ligament, or joint. [1]
What the evidence shows
Knee-pain research
A 2021 chart review contacted 16 people after knee injections of BPC-157 alone or with TB4. Reported pain improvement came from an uncontrolled, retrospective survey; it cannot establish tissue repair or a reliable treatment effect. [1]
Intravenous safety · two-person pilot
A 2025 uncontrolled pilot monitored two adults who had received intravenous BPC-157 previously. No short-term symptoms or changes in the measured laboratory markers were reported. Two selected participants and brief follow-up cannot establish general safety, uncommon risks, or injury-healing effectiveness. [2]
What remains unknown
Controlled evidence for injury healing, long-term safety, and a reliable time to benefit is not established by this study.
Safety
Safety uncertainty
Human safety information is limited. FDA flags immune-reaction and impurity concerns for this substance. [3]
Route matters
The safety pilot used intravenous administration in a clinic. Its observations do not validate oral, subcutaneous, or joint preparations, and cannot establish a general mixing method or shelf life. [2]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does less pain mean an injury healed?
No. A symptom report is different from imaging or measured tissue repair. The cited study did not establish structural healing.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain2021 · retrospective human study · PMID 34324435
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study2025 · uncontrolled safety pilot · 2 participants
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · safety information · accessed September 2026
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.